Renin Inhibition with Aliskiren: A Decade of Clinical Experience
Abstract
:1. Introduction
2. Aliskiren and Blood Pressure Lowering
2.1. Monotherapy
2.2. Combination
2.3. Special Populations
2.4. Real Life Data
3. Aliskiren and End-Organ Damage
3.1. Diabetics
3.2. Left Ventricular Hypertrophy
3.3. Acute Coronary Syndromes
3.4. Elderly
3.5. Coronary Atherosclerosis
3.6. Heart Failure
4. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
Abbreviations
References
- WHO Global Health Observatory (GHO) Data. Raised Blood Pressure; Situation and Trends. Available online: http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/ (accessed on 26 February 2017).
- Lim, S.S.; Vos, T.; Flaxman, A.D.; Danaei, G.; Shibuya, K.; Adair-Rohani, H.; Amann, M.; Anderson, H.R.; Andrews, K.G.; Aryee, M.; et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2224–2260. [Google Scholar] [CrossRef]
- World Health Organization. World Health Statistics—Monitoring Health For The Sdgs; World Health Organization: Geneva, Switzerland, 2016. [Google Scholar]
- SPRINT Research Group; Wright, J.T., Jr.; Williamson, J.D.; Whelton, P.K.; Snyder, J.K.; Sink, K.M.; Rocco, M.V.; Reboussin, D.M.; Rahman, M.; Oparil, S.; et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med. 2015, 373, 2103–2116. [Google Scholar] [PubMed]
- Nguyen, G.; Delarue, F.; Burcklé, C.; Bouzhir, L.; Giller, T.; Sraer, J.-D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Investig. 2002, 109, 1417–1427. [Google Scholar] [CrossRef] [PubMed]
- Danser, A.H.J. The Role of the (Pro)renin Receptor in Hypertensive Disease. Am. J. Hypertens. 2015, 28, 1187–1196. [Google Scholar] [CrossRef] [PubMed]
- Verma, S.; Gupta, M.; Holmes, D.T.; Xu, L.; Teoh, H.; Gupta, S.; Yusuf, S.; Lonn, E.M. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur. Heart J. 2011, 32, 2135–2142. [Google Scholar] [CrossRef] [PubMed]
- Masson, S.; Solomon, S.; Angelici, L.; Latini, R.; Anand, I.S.; Prescott, M.; Maggioni, A.P.; Tognoni, G.; Cohn, J.N. The Val-Heft Investigators. Investigators Elevated Plasma Renin Activity Predicts Adverse Outcome in Chronic Heart Failure, Independently of Pharmacologic Therapy: Data From the Valsartan Heart Failure Trial (Val-HeFT). J. Card. Fail. 2010, 16, 964–970. [Google Scholar] [CrossRef] [PubMed]
- Bhandari, S.K.; Batech, M.; Shi, J.; Jacobsen, S.J.; Sim, J.J. Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure. Kidney Res. Clin. Pract. 2016, 35, 219–228. [Google Scholar] [CrossRef] [PubMed]
- Hollenberg, N.K.; Fisher, N.D.; Price, D.A. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998, 32, 387–392. [Google Scholar] [CrossRef] [PubMed]
- Rahuel, J.; Rasetti, V.; Maibaum, J.; Rüeger, H.; Göschke, R.; Cohen, N.C.; Stutz, S.; Cumin, F.; Fuhrer, W.; Wood, J.M.; et al. Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. 2000, 7, 493–504. [Google Scholar] [CrossRef]
- Wood, J.M.; Maibaum, J.; Rahuel, J.; Grütter, M.G.; Cohen, N.-C.; Rasetti, V.; Rüger, H.; Göschke, R.; Stutz, S.; Fuhrer, W.; et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 2003, 308, 698–705. [Google Scholar] [CrossRef]
- Waldmeier, F.; Glaenzel, U.; Wirz, B.; Oberer, L.; Schmid, D.; Seiberling, M.; Valencia, J.; Riviere, G.-J.; End, P.; Vaidyanathan, S. Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers. Drug Metab. Dispos. 2007, 35, 1418–1428. [Google Scholar] [CrossRef] [PubMed]
- Vaidyanathan, S.; Maboudian, M.; Warren, V.; Yeh, C.-M.; Dieterich, H.A.; Howard, D.; Dole, W.P. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Curr. Med. Res. Opin. 2008, 24, 2313–2326. [Google Scholar] [CrossRef] [PubMed]
- Vaidyanathan, S.; Warren, V.; Yeh, C.; Bizot, M.-N.; Dieterich, H.A.; Dole, W.P. Pharmacokinetics, Safety, and Tolerability of the Oral Renin Inhibitor Aliskiren in Patients With Hepatic Impairment. J. Clin. Pharmacol. 2007, 47, 192–200. [Google Scholar] [CrossRef] [PubMed]
- Vaidyanathan, S.; Bigler, H.; Yeh, C.; Bizot, M.-N.; Dieterich, H.A.; Howard, D.; Dole, W.P. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin. Pharmacokinet. 2007, 46, 661–675. [Google Scholar] [CrossRef] [PubMed]
- Limoges, D.; Dieterich, H.A.; Yeh, C.-M.; Vaidyanathan, S.; Howard, D.; Dole, W.P. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int. J. Clin. Pharmacol. Ther. 2008, 46, 252–258. [Google Scholar] [CrossRef] [PubMed]
- Nussberger, J.; Wuerzner, G.; Jensen, C.; Brunner, H.R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril. Hypertension 2002, 39, E1–E8. [Google Scholar] [CrossRef] [PubMed]
- Oh, B.-H.; Mitchell, J.; Herron, J.R.; Chung, J.; Khan, M.; Keefe, D.L. Aliskiren, an Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Sustained 24-hour Blood Pressure Control in Patients with Hypertension. J. Am. Coll. Cardiol. 2007, 49, 1157–1163. [Google Scholar] [CrossRef] [PubMed]
- Stanton, A.V.; Gradman, A.H.; Schmieder, R.E.; Nussberger, J.; Sarangapani, R.; Prescott, M.F. Aliskiren Monotherapy Does Not Cause Paradoxical Blood Pressure Rises: Meta-Analysis of Data From 8 Clinical Trials. Hypertension 2010, 55, 54–60. [Google Scholar] [CrossRef] [PubMed]
- Danser, A.H.J.; Charney, A.; Feldman, D.L.; Nussberger, J.; Fisher, N.; Hollenberg, N. The Renin Rise with Aliskiren: It’s Simply Stoichiometry. Hypertension 2008, 51, e27–e28. [Google Scholar] [CrossRef] [PubMed]
- Stanton, A.; Jensen, C.; Nussberger, J.; O’Brien, E. Blood Pressure Lowering in Essential Hypertension with an Oral Renin Inhibitor, Aliskiren. Hypertension 2003, 42, 1137–1143. [Google Scholar] [CrossRef] [PubMed]
- Gradman, A.H.; Schmieder, R.E.; Lins, R.L.; Nussberger, J.; Chiang, Y.; Bedigian, M.P. Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients. Circulation 2005, 111, 1012–1018. [Google Scholar] [CrossRef] [PubMed]
- Kushiro, T.; Itakura, H.; Abo, Y.; Gotou, H.; Terao, S.; Keefe, D.L. Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension. Hypertens. Res. 2006, 29, 997–1005. [Google Scholar] [CrossRef] [PubMed]
- Pool, J.; Schmieder, R.; Azizi, M.; Aldigier, J.; Januszewicz, A.; Zidek, W.; Chiang, Y.; Satlin, A. Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan. Am. J. Hypertens. 2007, 20, 11–20. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, E.; Barton, J.; Nussberger, J.; Mulcahy, D.; Jensen, C.; Dicker, P.; Stanton, A. Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker. Hypertension 2007, 49, 276–284. [Google Scholar] [CrossRef] [PubMed]
- Jordan, J.; Engeli, S.; Boye, S.W.; le Breton, S.; Keefe, D.L. Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension. Hypertension 2007, 49, 1047–1055. [Google Scholar] [CrossRef] [PubMed]
- Strasser, R.H.; Puig, J.G.; Farsang, C.; Croket, M.; Li, J.; van Ingen, H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J. Hum. Hypertens. 2007, 21, 780–787. [Google Scholar] [CrossRef] [PubMed]
- Verdecchia, P.; Calvo, C.; Mockel, V.; Keeling, L.; Satlin, A. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press. 2007, 16, 381–391. [Google Scholar] [CrossRef] [PubMed]
- Drummond, W.; Munger, M.A.; Rafique Essop, M.; Maboudian, M.; Khan, M.; Keefe, D.L. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J. Clin. Hypertens. 2007, 9, 742–750. [Google Scholar] [CrossRef]
- Oparil, S.; Yarows, S.A.; Patel, S.; Fang, H.; Zhang, J.; Satlin, A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007, 370, 221–229. [Google Scholar] [CrossRef]
- Uresin, Y.; Taylor, A.; Kilo, C.; Tschöpe, D.; Santonastaso, M.; Ibram, G.; Fang, H.; Satlin, A. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin-Angiotensin-Aldosterone Syst. 2007, 8, 190–198. [Google Scholar] [CrossRef] [PubMed]
- Villamil, A.; Chrysant, S.G.; Calhoun, D.; Schober, B.; Hsu, H.; Matrisciano-Dimichino, L.; Zhang, J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 2007, 25, 217–226. [Google Scholar] [CrossRef] [PubMed]
- Andersen, K.; Weinberger, M.H.; Egan, B.; Constance, C.M.; Ali, M.A.; Jin, J.; Keefe, D.L. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial. J. Hypertens. 2008, 26, 589–599. [Google Scholar] [CrossRef] [PubMed]
- Dietz, R.; Dechend, R.; Yu, C.-M.; Bheda, M.; Ford, J.; Prescott, M.F.; Keefe, D.L. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1. J. Renin-Angiotensin-Aldosterone Syst. 2008, 9, 163–175. [Google Scholar] [CrossRef] [PubMed]
- Nickenig, G.; Simanenkov, V.; Lembo, G.; Rodriguez, P.; Salko, T.; Ritter, S.; Zhang, J. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press. Suppl. 2008, 2, 31–40. [Google Scholar] [CrossRef] [PubMed]
- Geiger, H.; Barranco, E.; Gorostidi, M.; Taylor, A.; Zhang, X.; Xiang, Z.; Zhang, J. Combination Therapy With Various Combinations of Aliskiren, Valsartan, and Hydrochlorothiazide in Hypertensive Patients Not Adequately Responsive to Hydrochlorothiazide Alone. J. Clin. Hypertens. 2009, 11, 324–332. [Google Scholar] [CrossRef] [PubMed]
- Kushiro, T.; Itakura, H.; Abo, Y.; Gotou, H.; Terao, S.; Keefe, D.L. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hypertens. Res. 2009, 32, 169–175. [Google Scholar] [CrossRef] [PubMed]
- Puig, J.G.; Schunkert, H.; Taylor, A.A.; Boye, S.; Jin, J.; Keefe, D.L. Evaluation of the dose—Response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Clin. Ther. 2009, 31, 2839–2850. [Google Scholar] [CrossRef] [PubMed]
- Blumenstein, M.; Romaszko, J.; Calderón, A.; Andersen, K.; Ibram, G.; Liu, Z.; Zhang, J. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr. Med. Res. Opin. 2009, 25, 903–910. [Google Scholar] [CrossRef] [PubMed]
- Littlejohn, T.W.; Trenkwalder, P.; Hollanders, G.; Zhao, Y.; Liao, W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr. Med. Res. Opin. 2009, 25, 951–959. [Google Scholar] [CrossRef] [PubMed]
- Schmieder, R.E.; Philipp, T.; Guerediaga, J.; Gorostidi, M.; Smith, B.; Weissbach, N.; Maboudian, M.; Botha, J.; van Ingen, H. Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren: A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide. Circulation 2009, 119, 417–425. [Google Scholar] [CrossRef] [PubMed]
- Duprez, D.A.; Munger, M.A.; Botha, J.; Keefe, D.L.; Charney, A.N. Aliskiren for Geriatric Lowering of Systolic Hypertension: A randomized controlled trial. J. Hum. Hypertens. 2010, 24, 600–608. [Google Scholar] [CrossRef] [PubMed]
- Black, H.R.; Kribben, A.; Aguirre Palacios, F.; Bijarnia, M.; Laflamme, A.K.; Baschiera, F. Aliskiren Alone or in Combination With Hydrochlorothiazide in Patients With the Lower Ranges of Stage 2 Hypertension: The ACQUIRE Randomized Double-Blind Study. J. Clin. Hypertens. 2010, 12, 917–926. [Google Scholar] [CrossRef] [PubMed]
- Ito, S.; Nakura, N.; Le Breton, S.; Keefe, D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens. Res. 2010, 33, 62–66. [Google Scholar] [CrossRef] [PubMed]
- Chrysant, S.G.; Murray, A.V.; Hoppe, U.C.; Dattani, D.; Patel, S.; Ritter, S.; Zhang, J. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Curr. Med. Res. Opin. 2010, 26, 2841–2849. [Google Scholar] [CrossRef] [PubMed]
- Palatini, P.; Jung, W.; Shlyakhto, E.; Botha, J.; Bush, C.; Keefe, D.L. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: Results of a randomized, double-blind study. J. Hum. Hypertens. 2010, 24, 93–103. [Google Scholar] [CrossRef] [PubMed]
- Fogari, R.; Zoppi, A.; Mugellini, A.; Lazzari, P.; Derosa, G. Different Effects of Aliskiren and Losartan on Fibrinolysis and Insulin Sensitivity in Hypertensive Patients with Metabolic Syndrome. Horm. Metab. Res. 2010, 42, 892–896. [Google Scholar] [CrossRef] [PubMed]
- Weir, M.R.; Yadao, A.M.; Purkayastha, D.; Charney, A.N. Effects of High- and Low-Sodium Diets on Ambulatory Blood Pressure in Patients With Hypertension Receiving Aliskiren. J. Cardiovasc. Pharmacol. Ther. 2010, 15, 356–363. [Google Scholar] [CrossRef] [PubMed]
- Ferdinand, K.C.; Weitzman, R.; Israel, M.; Lee, J.; Purkayastha, D.; Jaimes, E.A. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. J. Am. Soc. Hypertens. 2011, 5, 102–113. [Google Scholar] [CrossRef] [PubMed]
- Fogari, R.; Zoppi, A.; Mugellini, A.; Maffioli, P.; Lazzari, P.; Monti, C.; Derosa, G. Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: A three-way crossover study. Expert Opin. Pharmacother. 2011, 12, 1351–1358. [Google Scholar] [CrossRef] [PubMed]
- Basile, J.; Babazadeh, S.; Lillestol, M.; Botha, J.; Yurkovic, C.; Weitzman, R. Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy With Hydrochlorothiazide Monotherapy in Older Patients With Stage 2 Systolic Hypertension: Results of the ACTION Study. J. Clin. Hypertens. 2011, 13, 162–169. [Google Scholar] [CrossRef] [PubMed]
- Townsend, R.R.; Forker, A.D.; Bhosekar, V.; Yadao, A.; Keefe, D.L. Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus. J. Clin. Hypertens. 2011, 13, 889–897. [Google Scholar] [CrossRef] [PubMed]
- Brown, M.J.; McInnes, G.T.; Papst, C.C.; Zhang, J.; MacDonald, T.M. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): A randomised, parallel-group trial. Lancet 2011, 377, 312–320. [Google Scholar] [CrossRef]
- Sica, D.; Gradman, A.H.; Lederballe, O.; Kolloch, R.E.; Zhang, J.; Keefe, D.L. Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension. Clin. Drug Investig. 2011, 31, 1. [Google Scholar] [CrossRef] [PubMed]
- Ferdinand, K.C.; Pool, J.; Weitzman, R.; Purkayastha, D.; Townsend, R. Peripheral and Central Blood Pressure Responses of Combination Aliskiren/Hydrochlorothiazide and Amlodipine Monotherapy in African American Patients With Stage 2 Hypertension: The ATLAAST Trial. J. Clin. Hypertens. 2011, 13, 366–375. [Google Scholar] [CrossRef] [PubMed]
- Segura, J.; Cerezo, C.; Garcia-Donaire, J.A.; Schmieder, R.E.; Praga, M.; de la Sierra, A.; Ruilope, L.M. Validation of a therapeutic scheme for the treatment of resistant hypertension. J. Am. Soc. Hypertens. 2011, 5, 498–504. [Google Scholar] [CrossRef] [PubMed]
- Black, H.R.; Weinberger, M.H.; Purkayastha, D.; Lee, J.; Sridharan, K.; Israel, M.; Hilkert, R.; Izzo, J. Comparative Efficacy and Safety of Combination Aliskiren/Amlodipine and Amlodipine Monotherapy in African Americans With Stage 2 Hypertension. J. Clin. Hypertens. 2011, 13, 571–581. [Google Scholar] [CrossRef] [PubMed]
- Krone, W.; Hanefeld, M.; Meyer, H.-F.; Jung, T.; Bartlett, M.; Yeh, C.-M.; Rajman, I.; Prescott, M.F.; Dole, W.P. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J. Hum. Hypertens. 2011, 25, 186–195. [Google Scholar] [CrossRef] [PubMed]
- Drummond, W.; Sirenko, Y.M.; Ramos, E.; Baek, I.; Keefe, D.L. Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination. Am. J. Cardiovasc. Drugs 2011, 11, 327–333. [Google Scholar] [CrossRef] [PubMed]
- Schweizer, J.; Ulmer, H.-J.; Benduhn, H.; Klebs, S. Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (±amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg. Curr. Med. Res. Opin. 2011, 27, 131–140. [Google Scholar] [CrossRef] [PubMed]
- Zhu, J.-R.; Sun, N.-L.; Yang, K.; Hu, J.; Xu, G.; Hong, H.; Wang, R.; Tu, Y.-M.; Ritter, S.; Keefe, D. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertens. Res. 2012, 35, 28–33. [Google Scholar] [CrossRef] [PubMed]
- Flack, J.M.; Yadao, A.M.; Purkayastha, D.; Samuel, R.; White, W.B. Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with Stage 2 hypertension. J. Am. Soc. Hypertens. 2012, 6, 142–151. [Google Scholar] [CrossRef] [PubMed]
- Düsing, R.; Brunel, P.; Baek, I.; Baschiera, F. Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan. J. Hypertens. 2012, 30, 1029–1040. [Google Scholar] [CrossRef] [PubMed]
- Axthelm, C.; Sieder, C.; Meister, F.; Kaiser, E. Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg. Curr. Med. Res. Opin. 2012, 28, 69–78. [Google Scholar] [CrossRef] [PubMed]
- Fogari, R.; Zoppi, A.; Maffioli, P.; Monti, C.; Lazzari, P.; Mugellini, A.; Derosa, G. Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2012, 14, 341–347. [Google Scholar] [CrossRef] [PubMed]
- Pfeiffer, D.; Rennie, N.; Papst, C.C.; Zhang, J. Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥. Curr. Vasc. Pharmacol. 2012, 10, 773–780. [Google Scholar] [CrossRef] [PubMed]
- Villa, G.; Breton, S.; Le Ibram, G.; Keefe, D.L. Efficacy, Safety, and Tolerability of Aliskiren Monotherapy Administered With a Light Meal in Elderly Hypertensive Patients: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Evaluation Study. J. Clin. Pharmacol. 2012, 52, 1901–1911. [Google Scholar] [CrossRef] [PubMed]
- Lacourcière, Y.; Taddei, S.; Konis, G.; Fang, H.; Severin, T.; Zhang, J. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension. J. Hypertens. 2012, 30, 2047–2055. [Google Scholar] [CrossRef] [PubMed]
- Murray, A.V.; Koenig, W.; Garcia-Puig, J.; Patel, S.; Zhang, J. Safety and Efficacy of Aliskiren/Amlodipine/Hydrochlorothiazide Triple Combination in Patients With Moderate to Severe Hypertension: A 54-Week, Open-Label Study. J. Clin. Hypertens. 2012, 14, 821–827. [Google Scholar] [CrossRef] [PubMed]
- Glorioso, N.; Thomas, M.; Troffa, C.; Argiolas, G.; Patel, S.; Baek, I.; Zhang, J. Antihypertensive efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients with an inadequate response to aliskiren monotherapy. Curr. Vasc. Pharmacol. 2012, 10, 748–755. [Google Scholar] [CrossRef] [PubMed]
- Braun-Dullaeus, R.C.; Shustov, S.B.; Alvarez, C.; Rogelio, G.G.; Zhang, J.; Hristoskova, S.; Häring, D.A. Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: A randomised, double-blind, active comparator trial. Int. J. Clin. Pract. 2012, 66, 834–842. [Google Scholar] [CrossRef] [PubMed]
- Kanaoka, T.; Tamura, K.; Ohsawa, M.; Wakui, H.; Maeda, A.; Dejima, T.; Azushima, K.; Haku, S.; Mitsuhashi, H.; Yanagi, M.; et al. Effects of Aliskiren-Based Therapy on Ambulatory Blood Pressure Profile, Central Hemodynamics, and Arterial Stiffness in Nondiabetic Mild to Moderate Hypertensive Patients. J. Clin. Hypertens. 2012, 14, 522–529. [Google Scholar] [CrossRef] [PubMed]
- Littlejohn, T.W.; Jones, S.W.; Zhang, J.; Hsu, H.; Keefe, D.L. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: A randomized, double-blind, multifactorial study. J. Hum. Hypertens. 2013, 27, 321–327. [Google Scholar] [CrossRef] [PubMed]
- Mazza, A.; Montemurro, D.; Zuin, M.; Schiavon, L.; Zorzan, S.; Chondrogiannis, S.; Ferretti, A.; Ramazzina, E.; Rubello, D. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects. Minerva Cardioangiol. 2013, 61, 461–469. [Google Scholar] [PubMed]
- Bakris, G.L.; Oparil, S.; Purkayastha, D.; Yadao, A.M.; Alessi, T.; Sowers, J.R. Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus. J. Clin. Hypertens. 2013, 15, 92–100. [Google Scholar] [CrossRef] [PubMed]
- Yoshitomi, Y.; Kawanishi, K.; Yamaguchi, A.; Sakurai, S.; Minai, K.; Ishii, T.; Tarutani, Y.; Tsujibayashi, T.; Kaneki, M.; Saitou, Y.; et al. Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension. Int. Heart J. 2013, 54, 88–92. [Google Scholar] [CrossRef] [PubMed]
- Andreadis, E.A.; Angelopoulos, E.T.; Kolyvas, G.N.; Agaliotis, G.D.; Mousoulis, C.G.; Mousoulis, G.P. The effect of aliskiren versus ramipril-based treatment on the Ambulatory Arterial Stiffness Index in hypertensive patients. Int. Angiol. 2014, 33, 78–83. [Google Scholar] [PubMed]
- Imbalzano, E.; Scarpelli, M.; Mandraffino, G.; Creazzo, M.; Lizio, G.; Trapani, G.; Dattilo, G.; Dalbeni, A.; Tomasello, C.; Sardo, M.A.; et al. Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. J. Renin-Angiotensin-Aldosterone Syst. 2015, 16, 956–964. [Google Scholar] [CrossRef] [PubMed]
- Mizuno, H.; Hoshide, S.; Fukutomi, M.; Kario, K. Differing Effects of Aliskiren/Amlodipine Combination and High-Dose Amlodipine Monotherapy on Ambulatory Blood Pressure and Target Organ Protection. J. Clin. Hypertens. 2016, 18, 70–78. [Google Scholar] [CrossRef] [PubMed]
- Tani, S.; Kushiro, T.; Takahashi, A.; Kawamata, H.; Ohkubo, K.; Nagao, K.; Hirayama, A. Antihypertensive Efficacy of the Direct Renin Inhibitor Aliskiren as Add-on Therapy in Patients with Poorly Controlled Hypertension. Intern. Med. 2016, 55, 427–435. [Google Scholar] [CrossRef] [PubMed]
- Musini, V.M.; Fortin, P.M.; Bassett, K.; Wright, J.M. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: A Cochrane systematic review. J. Hum. Hypertens. 2009, 23, 495–502. [Google Scholar] [CrossRef] [PubMed]
- Verdecchia, P.; Angeli, F.; Mazzotta, G.; Martire, P.; Garofoli, M.; Gentile, G.; Reboldi, G. Aliskiren versus ramipril in hypertension. Ther. Adv. Cardiovasc. Dis. 2010, 4, 193–200. [Google Scholar] [CrossRef] [PubMed]
- Gao, D.; Ning, N.; Niu, X.; Wei, J.; Sun, P.; Hao, G. Aliskiren vs. Angiotensin Receptor Blockers in Hypertension: Meta-Analysis of Randomized Controlled Trials. Am. J. Hypertens. 2011, 24, 613–621. [Google Scholar] [CrossRef] [PubMed]
- Zheng, Z.; Shi, H.; Jia, J.; Li, D.; Lin, S. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension. J. Renin-Angiotensin-Aldosterone Syst. 2011, 12, 102–112. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Meng, L.; Shao, H.; Yu, F. Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: A meta-analysis. Hypertens. Res. 2013, 36, 252–261. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Chen, K.; Kou, X.; Han, Y.; Zhou, L.; Zeng, C. Aliskiren and Amlodipine in the Management of Essential Hypertension: Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2013, 8, e70111. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Yan, R.; Song, A.; Niu, X.; Cao, C.; Wei, J.; Dong, X.; Gao, D. Aliskiren/Amlodipine vs. Aliskiren/Hydrochlorothiazide in Hypertension: Indirect Meta-Analysis of Trials Comparing the Two Combinations vs. Monotherapy. Am. J. Hypertens. 2014, 27, 268–278. [Google Scholar] [CrossRef] [PubMed]
- Makani, H.; Bangalore, S.; Desouza, K.A.; Shah, A.; Messerli, F.H. Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials. BMJ 2013, 346, f360. [Google Scholar] [CrossRef] [PubMed]
- Bramlage, P.; Pittrow, D.; Wittchen, H.; Kirch, W.; Boehler, S.; Lehnert, H.; Hoefler, M.; Unger, T.; Sharma, A. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am. J. Hypertens. 2004, 17, 904–910. [Google Scholar] [CrossRef] [PubMed]
- Schmieder, R.E.; Philipp, T.; Guerediaga, J.; Gorostidi, M.; Bush, C.; Keefe, D.L. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: Sub-analysis of a 52-week, randomized, double-blind trial. J. Hypertens. 2009, 27, 1493–1501. [Google Scholar] [CrossRef] [PubMed]
- Verpooten, G.A.; Aerts, A.; Coen, N.; Vancayzeele, S.; Hermans, C.; Bowles, J.; MacDonald, K.; Abraham, I.; Lee, C.S. Antihypertensive effectiveness of aliskiren for the “real-world” management of hypertension: Multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). Int. J. Clin. Pract. 2011, 65, 54–63. [Google Scholar] [CrossRef] [PubMed]
- Volpe, M.; Tocci, G.; Bianchini, F.; De Rosa, M.; Fedozzi, E.; Covezzoli, A.; Maggioni, A.P. AIFA Drug Monitoring Program: Aliskiren Registry Use of aliskiren in a “real-life” model of hypertension management. J. Hypertens. 2011, 30, 1. [Google Scholar] [CrossRef] [PubMed]
- Maddury, S.R.; Pande, A.; Haque, K.M.; Echtay, A.; Go, L.; Gulzar, T.; Kadwa, M.; Hristoskova, S. Effectiveness and Safety of Aliskiren and Aliskiren Hydrochlorothiazide (HCT) in a Multiethnic, Real-World Setting. Adv. Ther. 2013, 30, 176–189. [Google Scholar] [CrossRef] [PubMed]
- Zeymer, U.; Dechend, R.; Riemer, T.; Kaiser, E.; Senges, J.; Pittrow, D.; Schmieder, R.E. 3A Registry Investigators 1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: Prospective 3A registry. Int. J. Cardiol. 2014, 176, 589–594. [Google Scholar] [CrossRef] [PubMed]
- Rosenkranz, A.R.; Ratzinger, M. Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study. Wien. Klin. Wochenschr. 2015, 127, 203–209. [Google Scholar] [CrossRef] [PubMed]
- Parving, H.-H.; Persson, F.; Lewis, J.B.; Lewis, E.J.; Hollenberg, N.K. AVOID Study Investigators Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2008, 358, 2433–2446. [Google Scholar] [CrossRef] [PubMed]
- McMurray, J.J.V.; Pitt, B.; Latini, R.; Maggioni, A.P.; Solomon, S.D.; Keefe, D.L.; Ford, J.; Verma, A.; Lewsey, J. Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. Circ. Hear. Fail. 2008, 1, 17–24. [Google Scholar] [CrossRef] [PubMed]
- Solomon, S.D.; Appelbaum, E.; Manning, W.J.; Verma, A.; Berglund, T.; Lukashevich, V.; Cherif Papst, C.; Smith, B.A.; Dahlof, B. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy. Circulation 2009, 119, 530–537. [Google Scholar] [CrossRef] [PubMed]
- Scirica, B.M.; Morrow, D.A.; Bode, C.; Ruzyllo, W.; Ruda, M.; Oude Ophuis, A.J.M.; Lopez-Sendon, J.; Swedberg, K.; Ogorek, M.; Rifai, N.; et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: The results of the AVANT GARDE-TIMI 43 Trial. Eur. Heart J. 2010, 31, 1993–2005. [Google Scholar] [CrossRef] [PubMed]
- Solomon, S.D.; Hee, S.; Shah, A.; Skali, H.; Desai, A.; Kober, L.; Maggioni, A.P.; Rouleau, J.L.; Kelly, R.Y.; Hester, A.; et al. Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J. 2011, 32, 1227–1234. [Google Scholar] [CrossRef] [PubMed]
- Parving, H.-H.; Brenner, B.M.; McMurray, J.J.V.; de Zeeuw, D.; Haffner, S.M.; Solomon, S.D.; Chaturvedi, N.; Persson, F.; Desai, A.S.; Nicolaides, M.; et al. ALTITUDE Investigators Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N. Engl. J. Med. 2012, 367, 2204–2213. [Google Scholar] [CrossRef] [PubMed]
- Nicholls, S.J.; Bakris, G.L.; Kastelein, J.J.P.; Menon, V.; Williams, B.; Armbrecht, J.; Brunel, P.; Nicolaides, M.; Hsu, A.; Hu, B.; et al. Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension. JAMA 2013, 310, 1135. [Google Scholar] [CrossRef] [PubMed]
- Teo, K.K.; Pfeffer, M.; Mancia, G.; O’Donnell, M.; Dagenais, G.; Diaz, R.; Dans, A.; Liu, L.; Bosch, J.; Joseph, P.; et al. Aliskiren Prevention of Later Life Outcomes trial Investigators Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: The APOLLO trial. Eur. Heart J. 2014, 35, 1743–1751. [Google Scholar] [CrossRef] [PubMed]
- Gheorghiade, M.; Böhm, M.; Greene, S.J.; Fonarow, G.C.; Lewis, E.F.; Zannad, F.; Solomon, S.D.; Baschiera, F.; Botha, J.; Hua, T.A.; et al. ASTRONAUT Investigators and Coordinators, for the Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA 2013, 309, 1125. [Google Scholar] [CrossRef] [PubMed]
- McMurray, J.J.V.; Krum, H.; Abraham, W.T.; Dickstein, K.; Køber, L.V.; Desai, A.S.; Solomon, S.D.; Greenlaw, N.; Ali, M.A.; Chiang, Y.; et al. ATMOSPHERE Committees Investigators Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N. Engl. J. Med. 2016, 374, 1521–1532. [Google Scholar] [CrossRef] [PubMed]
- McMurray, J.J.V.; Abraham, W.T.; Dickstein, K.; Køber, L.; Massie, B.M.; Krum, H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur. J. Heart Fail. 2012, 14, 341–343. [Google Scholar] [CrossRef] [PubMed]
- Raptis, A.E.; Markakis, K.P.; Mazioti, M.C.; Ikonomidis, I.; Maratou, E.P.; Vlahakos, D.V.; Kotsifaki, E.E.; Voumvourakis, A.N.; Tsirogianni, A.G.; Lambadiari, V.A.; et al. Effect of Aliskiren on Circulating Endothelial Progenitor Cells and Vascular Function in Patients With Type 2 Diabetes and Essential Hypertension. Am. J. Hypertens. 2015, 28, 22–29. [Google Scholar] [CrossRef] [PubMed]
- Bonadei, I.; Vizzardi, E.; D’Aloia, A.; Sciatti, E.; Raddino, R.; Metra, M. Role of Aliskiren on Arterial Stiffness and Endothelial Function in Patients With Primary Hypertension. J. Clin. Hypertens. 2014, 16, 202–206. [Google Scholar] [CrossRef] [PubMed]
- Fukutomi, M.; Hoshide, S.; Mizuno, H.; Kario, K. Differential Effects of Aliskiren/Amlodipine Combination and High-Dose Amlodipine Monotherapy on Endothelial Function in Elderly Hypertensive Patients. Am. J. Hypertens. 2014, 27, 14–20. [Google Scholar] [CrossRef] [PubMed]
First Author | Year/Country Study Type | Arms | Participants | Main Findings |
---|---|---|---|---|
Stanton A. [22] | 2003 Ireland RCT | ALI 37.5; 75; 150; 300; LOS 100 | 226 Mild-to-moderate hypertension | Dose-dependent reductions in ambulatory BP and decreased PRA were observed with ALI. Changes following 75, 150, and 300 mg of ALI were not significantly different to those observed with 100 mg of LOS. |
Gradman A.H. [23] | 2005 USA RCT | ALI 150; 300; 600; IRB 150; Placebo | 652 Mild-to-moderate hypertension | Oral ALI showed an effective BP lowering effect. ALI 300 and 600 mg lowered msDBP significantly more than IRB 150 mg. ALI 150 mg had a similar antihypertensive effect to IRB 150 mg. |
Kushiro T. [24] | 2006 Japan RCT | ALI 75; 150; 300; Placebo | 455 Japanese Mild-to-moderate hypertension | Once-daily oral ALI provided significant, dose-dependent reductions in msSBP/DBP with placebo-like tolerability in Japanese patients with hypertension. |
Pool J.L. [25] | 2007 Multicenter RCT | ALI 75; 150; 300; VAL 80; 120; 360; ALI/VAL; VAL/HCTZ; Placebo | 1123 Mild-to-moderate hypertension | ALI monotherapy produced dose-related reductions in DBP/SBP similar to VAL monotherapy and placebo-like tolerability. The combination of the two showed additive results with similar tolerability. |
O’Brien E. [26] | 2007 Ireland RCT | ALI 150; RAM 5; IRB 150; ALI/HCTZ; ALI/RAM; ALI/IRB | 67 Mild-to-moderate hypertension | ALI combined with HCTZ, RAM, or IRB, demonstrated significantly greater BP reductions than any agent monotherapy and also neutralized the compensatory rise in PRA stimulated by the other antihypertensive agents. |
Jordan J. [27] | 2007 Multicenter RCT | ALI/HCTZ; AML/HCTZ; IRB/HCTZ; Placebo/HCTZ | 489 Obese Mild-to-moderate hypertension | ALI/HCTZ showed significantly greater BP reductions than HCTZ alone, but similar to AML/HCTZ and IRB/HCTZ in obese hypertensive individuals. The ALI combination also neutralized the compensatory rise in PRA. |
Strasser R.H. [28] | 2007 Multicenter RCT | ALI 300; LIS 40; ALI/HCTZ; LIS/HCTZ | 153 Severe hypertension | ALI 300 mg monotherapy or ALI/HCTZ combination demonstrated similar efficacy and tolerability to LIS 40 mg monotherapy or LIS/HCTZ combination respectively in patients with severe hypertension. |
Verdecchia P. [29] | 2007 Multicenter RCT | ALI 75; 150; 300; LIS 10 | 355 (≥65 years old) Mild-to-moderate hypertension | ALI 75/150/300 mg and LIS 10mg lowered ambulatory SBP and office msSBP with no significant difference between ALI doses and no evidence of dose-related increases in the incidence of AEs. |
Oh B.H. [19] | 2007 Multicenter RCT | ALI 150; 300; 600; Placebo | 672 Mild-to-moderate hypertension | ALI 150 to 600 mg once daily, provided significant antihypertensive efficacy and placebo-like tolerability. The lowering effect of ALI 600 mg was greater but not statistically significant of that of ALI 300 mg. |
Drummond W. [30] | 2007 Multicenter RCT | AML 5; 10; ALI/AML | 545 Mild-to-moderate hypertension | ALI/AML 150/5 mg demonstrated greater BP lowering efficacy than AML 5 mg monotherapy but similar to AML 10 mg, although less edema was noted with the combination treatment. |
Oparil S. [31] | 2007 Multicenter RCT | ALI 300; VAL 320; ALI/VAL; Placebo | 1797 Mild-to-moderate hypertension | ALI/VAL 300/320 mg significantly lowered msDBP as compared to either component monotherapy or placebo. Safety and tolerability profiles were similar in all groups. |
Uresin Y. [32] | 2007 Multicenter RCT | ALI 300; RAM 10; ALI/RAM | 837 DM Mild-to-moderate hypertension | ALI 300 mg provided additional, significant BP reductions when combined with RAM 10 mg in patients with hypertension and diabetes mellitus. |
Villamil A. [33] | 2007 Multicenter RCT | ALI 75; 150; 300; HCTZ 6.25; 12.5; 25; ALI/HTCZ; Placebo | 2776 Mild-to-moderate hypertension | ALI/HCTZ combination produced a greater reduction in BP measurements and achieved better control rates and more responders than either monotherapy. HCTZ monotherapy increased PRA, but PRA decreased in the ALI monotherapy and the combination groups |
Andersen K. [34] | 2008 Iceland RCT | ALI 300; RAM 10; ALI/HCTZ; RAM/HCTZ | 687 Mild-to-moderate hypertension | ALI based therapy, alone or with HCTZ, produced greater msSBP/DBP reductions, better control rates, and more sustained effects after drug discontinuation than RAM based therapy. |
Dietz R. [35] | 2008 Multicenter RCT | ALI 300; ATEN 100; ALI/ATEN | 694 Mild-to-moderate hypertension | ALI/ATEN induced significantly greater msSBP reductions than ALI or ATEN alone, and msDBP reductions were larger with ATEN than with ALI. All three regimens reduced mean PRA from baseline. ALI treatment had lower rates of AEs and was not associated with bradycardia. |
Nickenig G. [36] | 2008 Multicenter RCT | ALI 300; ALI/HCTZ | 880 Non-responders to ALI monotherapy Mild-to-moderate hypertension | ALI/HCTZ 300/25 mg and 300/12.5 mg produced significantly greater msSBP/DBP reductions from baseline as well as higher BP control rates than ALI 300 mg alone with similar tolerability. |
Geiger H. [37] | 2009 Multicenter RCT | HCTZ 25; ALI/HCTZ; VAL/HCTZ; ALI/VAL/HCTZ | 641 Non-responders to HCTZ monotherapy; Mild-to-moderate hypertension | The ALI/VAL/HCTZ 300/320/25 mg arm produced statistically significant additional reductions in SBP/DBP and higher control rates than the ALI/HCTZ 300/25 mg, VAL/HCTZ 320/25 mg combinations and the HCTZ 25 mg monotherapy. The safety profile of the triple combination was similar to that of the double combinations. |
Kushiro T. [38] | 2009 Multicenter RCT | ALI 300; ALI/diuretic; ALI/CCB | 345 Japanese Mild-to-moderate hypertension | ALI monotherapy, as well as combinations of ALI/diuretic and ALI/CCB, achieved clinically significant msSBP/DBP reductions. All regimens were well tolerated, and the overall responder rate was high. |
Puig J.G. [39] | 2009 Multicenter RCT | ALI 75; 150; 300; Placebo | 642 Mild-to-moderate hypertension | Dose-related BP reductions were observed with ALI 75, 150, and 300 mg, but only the reductions achieved with ALI 150 and 300 mg were statistically significant compared to placebo. All doses were well tolerated. |
Blumenstein M. [40] | 2009 Multicenter RCT | HCTZ 25; ALI/HCTZ 150/25; 300/25 | 722 Non-responders to HCTZ monotherapy; Mild-to-moderate hypertension | Single pill ALI/HCTZ 300/25 mg and 150/25 mg combinations significantly lowered msSBP/DBP with the 300/25 mg combination producing the greater reductions. Responder rates were also significantly higher with ALI/HCTZ combinations. ALI/HCTZ showed similar tolerability to HCTZ monotherapy and a numerically lower incidence of hypokalemia. |
Littlejohn T.W. III [41] | 2009 Multicenter Non RCT | ALI/AML 300/10 ± HCTZ | 556 Mild-to-moderate hypertension | ALI/AML 300/10 mg, with or without add-on HCTZ, effectively reduced BP, especially in patients with stage 2 hypertension. The most common AE was peripheral edema. |
Schmieder R.E. [42] | 2009 Multicenter RCT | ALI 300; HCTZ 25; Placebo ± AML | 1124 Mild-to-moderate hypertension | ALI based therapy produced significantly greater BP reductions and higher responder rates than HCTZ based therapy. AE rates were similar in all groups with hypokalemia being more frequent in HCTZ based therapy. |
Duprez D.A. [43] | 2010 USA RCT | ALI 300; RAM 10 ± HCTZ or AML | 901 (≥65 years old) Mild-to-moderate hypertension | ALI monotherapy in elders with essential hypertension showed greater msSDB/DBP reductions and higher control rates than RAM monotherapy. Also fewer patients required add-on treatment with HCTZ or AML. Tolerability was similar, but the RAM group had a higher incidence of cough. |
Black H.R. [44] | 2010 Multicenter RCT | ALI 300; ALI/HCTZ | 688 160 mm Hg ≤ SBP < 180 mm Hg | ALI 300 mg monotherapy, as well as ALI/HCTZ 300/25 mg, produced substantial BP reductions from baseline with the reductions being significantly greater in the combination therapy. |
Ito S. [45] | 2010 Japan Non RCT | ALI 75→300 | 40 Japanese Renal dysfunction; Mild-to-moderate hypertension | 65% of the patients achieved BP response and 30% BP control with ALI monotherapy. The AE profile was low, and similar to studies with hypertensive patients without renal dysfunction. |
Chrysant S.G. [46] | 2010 Multicenter Non RCT | ALI/VAL 300/320 ± HCTZ | 601 Mild-to-moderate hypertension | ALI/VAL 300/320 mg with or without optional HCTZ addition showed clinically significant BP-lowering effects, high BP control rates and was well-tolerated with a very low incidence of hyperkalemia in patients with hypertension. |
Palatini P. [47] | 2010 Multicenter RCT | ALI 300; IRB 300; RAM 10 | 654 Mean ambulatory DBP ≥ 85 mm Hg | ALI 300 mg provided similar BP-lowering effects with IRB 300 mg and significantly greater than RAM 10 mg. The maintenance of the mean ambulatory SBP/DBP lowering effect of ALI was significantly greater when compared to both IRB and RAM monotherapies. |
Fogari R. [48] | 2010 Italy RCT | ALI 300; LOS 100 | 76 Metabolic syndrome Mild-to-moderate hypertension | Both ALI 300 mg and LOS 100 mg induced a significant and similar SBP/DBP reduction. tPA activity decreased with LOS and did not change significantly with ALI. Insulin sensitivity was also improved with ALI and remained unchanged with LOS. |
Weir M.R. [49] | 2010 Multicenter RCT | ALI 300 + ≥ 200 mmol/d Na; ALI 300 + ≤ 100 mmol/d Na | 132 135 mm Hg ≤ SBP < 160 mm Hg | During ALI 300 mg treatment, ambulatory SBP was significantly lower with the low-sodium diet compared to the high-sodium diet. Responder rates were also significantly higher with the low sodium diet. |
Ferdinand K.C. [50] | 2011 USA RCT | ALI/AML/HCTZ 300/10/25; ALI/AML 300/10 | 412 US minority Stage 2 hypertension | ALI/AML/HCTZ 300/10/25 mg produced greater msSBP reductions and higher responder rates than ALI/AML 300/10 mg therapy in self-identified US minority patients. Both combinations showed similar tolerability |
Fogari R. [51] | 2011 Italy RCT | ALI 300; AML 10; ALI/AML | 120 Mild-to-moderate hypertension | ALI 300 mg and AML 10 mg monotherapies produced similar SBP/DBP reductions. Their combination induced greater BP reductions than both monotherapies and a lower increase in ankle-foot volume than AML monotherapy. PRA was unaffected by AML, and it was reduced by both ALI monotherapy and ALI/AML combination. |
Basile J. [52] | 2011 USA RCT | ALI/HCTZ 300/25; HCTZ 25 ± AML | 451 (≥55 years old) 160 mm Hg ≤ SBP < 200 mm Hg | ALI/HCTZ 300/25 mg therapy provides significantly greater BP reductions and higher control rates than HCTZ 25 mg monotherapy with or without the optional addition of AML in older patients with stage 2 hypertension. |
Townsend R.R. [53] | 2011 USA RCT | ALI/HCTZ 300/25; AML 10 | 860 DM 160 mm Hg ≤ SBP < 200 mm Hg | ALI/HCTZ 300/25 mg produced greater msSBP reductions and higher control rates than AML 10 mg. msDBP reductions were similar in both groups. Both treatments were well tolerated, although AE incidence and discontinuation were higher in the AML group. |
Brown M.J. [54] | 2011 Multicenter RCT | ALI/Placebo; AML/Placebo; ALI/AML | 1254 150 mm Hg ≤ SBP < 180 mm Hg | ALI/AML 300/10 mg treatment showed higher SBP reductions than either monotherapy. ALI/AML combination could be recommended for initial treatment for BP ≥ 150 mm Hg. |
Sica D. [55] | 2011 Multicenter RCT | ALI 150; 300 ± HCTZ | 1955 Mild-to-moderate hypertension | Long-term treatment with ALI with or without additional HCTZ is well tolerated and provides effective BP reductions that are sustained over one year. |
Ferdinand K.C. [56] | 2011 USA RCT | ALI/HCTZ 300/25; AML 10 | 332 160 mm Hg ≤ SBP < 200 mm Hg | ALI/HCTZ 300/25 mg and AML 10 mg produced similar msSBP/DBP and 24-h ambulatory SBP reductions. Central SBP reductions, measured in a smaller subgroup, were greater in the ALI/HCTZ arm. BP control rates were similar in both groups. |
Segura J. [57] | 2011 Spain Non RCT | ALI/AML/CHLOR 300/10/50 | 76 Treatment-resistant hypertension | ALI/AML/CHLOR 300/10/50 mg treatment showed effective BP lowering effects in patients with treatment-resistant hypertension not responding to spironolactone. |
Black H.R. [58] | 2011 USA RCT | ALI/AML 300/10; AML 10 | 443 African American 160 mm Hg ≤ SBP < 200 mm Hg | ALI/AML 300/10 mg produced greater msSBP reductions and higher responder rates than AML 10 mg monotherapy. |
Krone W. [59] | 2011 Multicenter RCT | ALI 300; IRB 300 | 141 Hypertension and Metabolic syndrome | ALI 300 mg provided significantly greater BP reductions and higher control rates than IRB 300 mg. Both treatments had similar effects on lipid and glucose profiles. |
Drummond W. [60] | 2011 USA RCT | VAL/HCTZ/ALI 160/25/300; VAL/HCTZ/Placebo | 363 DM msDBP ≥ 95 mm Hg inadequately controlled with VAL/HCTZ | BP reductions with ALI 300 mg added to VAL/HCTZ 160/25 mg were numerically greater compared with placebo added to VAL/HCTZ, but not statistically significant. |
Schweizer J. [61] | 2011 Germany Non RCT | ALI/HCTZ 300/25 ± AML | 123 100 mm Hg ≤ DBP < 110 mm Hg inadequately controlled with CAN/HCTZ | Patients inadequately controlled with CAN/HCTZ 32/25 mg achieved clinically and statistically significant BP reductions with the single pill combination of ALI /HCTZ 300/25 mg and the optional addition of AML 5 mg. |
Zhu J.R. [62] | 2012 Multicenter RCT | ALI 75; 150; 300; RAM 5 | 1316 Asian Mild-to-moderate hypertension | ALI in doses of 75,150, and 300 mg produced greater BP reductions and higher control rates than RAM 5 mg, but only the differences with ALI 300 mg were statistically significant. |
Flack J.M. [63] | 2012 Multicenter RCT | ALI/VAL 300/320; VAL 320 | 451 Stage 2 hypertension | ALI/VAL 300/320 mg significantly reduced msSBP than VAL 320 mg alone. Even greater differences were observed in 24-h ambulatory BP measurements in a small subgroup of 76 patients. |
Düsing R. [64] | 2012 Multicenter RCT | ALI 300; TEL 80 | 822 Essential hypertension | ALI 300 mg and TEL 80 mg produced similar mean ambulatory SBP reductions. During a seven-day treatment withdrawal, ALI showed a more sustained BP-lowering effect than TEL. |
Axthelm C. [65] | 2012 Multicenter Non RCT | ALI/AML 300/10 ± HCTZ | 342 Stage 2 hypertension Not controlled by OLM/AML 40/10 mg | ALI/AML 300/10 mg with the optional addition of HCTZ 12.5 mg achieved clinically and statistically significant BP reductions in patients inadequately controlled by OLM/AML 40/10 mg. |
Fogari R. [66] | 2012 Italy RCT | ALI 300; AML 10; Placebo | 170 DM (50–75 years old) Mild-to-moderate hypertension | ALI and AML both, significantly reduced SBP/DBP with no statistical difference between them. Only ALI reduced QT duration and dispersion. |
Pfeiffer D. [67] | 2012 Multicenter RCT | ALI/AML 300/10; 150/10; AML 10 | 847 Mild-to-moderate hypertension Not controlled by AML monotherapy | ALI/AML 300/10 and 150/10 mg provided significantly greater msSBP/DBP reductions than AML 10 mg monotherapy. Higher control rates were achieved in the ALI/AML 300/10 mg arm over the AML 10 mg arm. |
Villa G. [68] | 2012 Multicenter RCT | ALI 75; 150; 300; Placebo | 754 (≥65years old) 150 mm Hg ≤ msSBP < 180 mm Hg | ALI 75, 150, and 300 mg provided significantly greater msSBP/DBP reductions compared to placebo. The estimated minimum effective dose was 81.9 mg. |
Lacourcière Y. [69] | 2012 Multicenter RCT | ALI/AML/HCTZ; ALI/AML; ALI/HCTZ; AML/HCTZ | 1191 Moderate-to-severe hypertension | ALI/AML/HCTZ 300/10/25 mg produced statistically superior msSBP/DBP reductions and higher control rates as compared to the ALI/AML, ALI/HCTZ, and AML/HCTZ dual combinations. |
Murray A.V. [70] | 2012 Multicenter Non RCT | ALI/AML/HCTZ 300/10/25 | 564 Moderate-to-severe hypertension | ALI/AML/HCTZ 300/10/25 mg provided statistically significant msSBP/DBP reductions, high BP control rates and was well tolerated. |
Glorioso N. [71] | 2012 Multicenter RCT | ALI/AML 300/10; 300/5; ALI 300 | 818 Mild-to-moderate hypertension | ALI/AML 300/10 and 300/5 mg provided significantly greater msSBP/DBP reductions and higher BP control rates than ALI 300 mg alone. |
Braun-Dullaeus R.C. [72] | 2012 Multicenter RCT | ALI/AML 300/10; AML 10 | 485 Moderate-to-severe hypertension | ALI/AML 300/10 mg produced significantly greater msSBP/DBP reductions and BP control rates than AML 10 mg monotherapy. Both groups had a similar incidence of AEs. |
Kanaoka T. [73] | 2012 Japan Non RCT | ALI 150→300 | 21 Nondiabetic Japanese Mild-to-moderate hypertension | ALI 300 mg significantly reduced clinic, ambulatory and central BP measurements. Brachial-ankle pulse wave velocity, a marker of arterial stiffness, also significantly decreased from baseline. |
Littlejohn T.W. III [74] | 2013 Multicenter RCT | ALI 150; 300; AML 5; 10; ALI/AML; Placebo | 1688 95 mm Hg ≤ msDBP < 110 mm Hg | ALI/AML (150 or 300 mg)/ (5 or 10 mg) combinations provided greater BP reductions than either agent alone. |
Mazza A [75] | 2013 Italy Non RCT | ALI 150–300 | 106 Resistant hypertension Mild renal dysfunction | ALI 150–300 mg significantly reduced clinic and ambulatory BP measurements, left ventricular mass index and did not affect eGFR. |
Bakris G.L. [76] | 2013 USA RCT | ALI/VAL 300/320; VAL 320 | 1143 DM Hypertension Stage 1 or 2 CKD | ALI/VAL 300/320 mg provided additive BP reductions and similar tolerability to VAL 320 mg alone in diabetic patients with early stage CKD. |
Yoshitomi Y. [77] | 2013 Japan Non RCT | ALI 150 add-on | 43 Resistant hypertension | ALI 150 mg added to the existing regimen provided greater BP control rates and was effective as a fourth or fifth line agent. |
Andreadis E.A. [78] | 2014 Greece RCT | ALI 300; RAM 5± HCTZ or AML | 154 Naïve or 6 mo untreated | ALI based therapy produced similar SBP/DBP reductions to RAM based therapy. Both therapies reduced the ambulatory arterial stiffness index. |
Imbalzano E. [79] | 2015 Italy RCT | ALI add-on; RAM or LOS add-on | 126 DM Microalbuminuria Uncontrolled BP | ALI addition to optimal therapy provided higher BP and microalbuminuria reductions compared with the addition of RAM or LOS. |
Mizuno H. [80] | 2016 Japan RCT | ALI/AML 150–300/5; AML 10 | 105 Japanese elderly Essential hypertension | ALI/AML 150–300/5 mg and AML 10 mg produced similar reductions in 24-h SBP, and daytime/nighttime SBP. ALI/AML significantly reduced UACR more than high dose AML, but it was significantly less effective in reducing morning BP surge and early morning BP. |
Tani S. [81] | 2016 Japan Non RCT | ALI add-on | 79 Uncontrolled BP | ALI addition to existing regimens provided higher control rates and made it possible to reduce the number of drugs in treatment combinations. No renal function worsening was observed in patients receiving other RAAS inhibitors. |
Study | Type | Arms | Participants | Results |
---|---|---|---|---|
AVOID (2008) [97] | Multicenter RCT | ALI/LOS; Placebo/LOS | 599 with DM and nephropathy. | ALI significantly reduced UACR compared to placebo. Both arms showed similar BP reductions and AEs. |
ALOFT (2008) [98] | Multicenter RCT | ALI 150; Placebo | 302 with NYHA class II-IV HF treated with an ACEI or ARB and a beta blocker. | Significant plasma NT-proBNP reductions were observed in the ALI arm compared to placebo. |
ALLAY (2009) [99] | Multicenter RCT | ALI 300; LOS 100; ALI/LOS | 465 with hypertension, BMI > 25 kg/m2, and increased ventricular wall thickness. | In both ALI and LOS arms similar left ventricular mass reductions were observed. Their combination produced similar results with LOS monotherapy. |
AVANT GARDE-TIMI 43 (2010) [100] | Multicenter RCT | ALI; VAL; ALI/VAL; Placebo | 1101 after acute coronary syndrome without evident HF. | All groups showed similar reductions of NT-proBNP levels. Active therapy groups had a higher incidence of AEs and similar clinical outcomes. |
ASPIRE (2011) [101] | Multicenter RCT | ALI; Placebo | 820 post-MI, LVEF ≤ 45%, and regional wall motion abnormalities. | No change in left ventricular end-systolic volume was observed when ALI was added to standard treatment compared to placebo. |
ALTITUDE (2012) [102] | Multicenter RCT | ACEI or ARB/ALI; ACEI or ARB/Placebo | 8562 with DM, and CKD, and/or CVD. | Discontinued due to higher incidence of AEs and non-fatal strokes in the ALI arm. |
AQUARIUS (2013) [103] | Multicenter RCT | ALI 300; Placebo | 613 with coronary artery disease, prehypertension, and two additional CVD factors. | ALI compared with placebo did not improve or slow the progression of coronary atherosclerosis. |
APOLLO (2014) [104] | Multicenter RCT | ALI/HCTZ or AML; ALI/Placebo; HCTZ or AML/Placebo; Placebo/Placebo | 1759 elders, SBP ≥ 130 mm Hg and < 160 mm Hg. | Discontinued early. There may be a benefit for substantial CVD reduction with the use of multiple BP-lowering drugs in elder hypertensive individuals. |
ASTRONAUT (2013) [105] | Multicenter RCT | ALI 150→300; Placebo | 1639 with a LVEF ≤ 40%, [BNP] ≥ 400 pg/mL or [NT-proBNP] ≥ 1600 pg/mL, and fluid overload symptoms. | ALI addition did not reduce cardiovascular death or HF rehospitalization compared to placebo, and had a higher incidence of AEs. |
ATMOSPHERE (2016) [106] | Multicenter RCT | ENA 5 or 10; ALI 300; ENA/ALI | 7016 with HF and a reduced ejection fraction. | Noninferiority was not proved for ALI when compared to ENA for the outcome of death from a cardiovascular cause or hospitalization for HF. |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pantzaris, N.-D.; Karanikolas, E.; Tsiotsios, K.; Velissaris, D. Renin Inhibition with Aliskiren: A Decade of Clinical Experience. J. Clin. Med. 2017, 6, 61. https://doi.org/10.3390/jcm6060061
Pantzaris N-D, Karanikolas E, Tsiotsios K, Velissaris D. Renin Inhibition with Aliskiren: A Decade of Clinical Experience. Journal of Clinical Medicine. 2017; 6(6):61. https://doi.org/10.3390/jcm6060061
Chicago/Turabian StylePantzaris, Nikolaos-Dimitrios, Evangelos Karanikolas, Konstantinos Tsiotsios, and Dimitrios Velissaris. 2017. "Renin Inhibition with Aliskiren: A Decade of Clinical Experience" Journal of Clinical Medicine 6, no. 6: 61. https://doi.org/10.3390/jcm6060061
APA StylePantzaris, N.-D., Karanikolas, E., Tsiotsios, K., & Velissaris, D. (2017). Renin Inhibition with Aliskiren: A Decade of Clinical Experience. Journal of Clinical Medicine, 6(6), 61. https://doi.org/10.3390/jcm6060061